サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1790294

関節内補充療法の市場規模、シェア、動向分析レポート：製品別、最終用途別、地域別、セグメント予測、2025年～2033年

Viscosupplementation Market Size, Share & Trends Analysis Report By Product (Single, Three & Five Injections), By End Use (Hospitals & Orthopedic Clinics/ASCs), By Region (North America, Europe, APAC, LATAM & MEA), And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 118 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
関節内補充療法の市場規模、シェア、動向分析レポート：製品別、最終用途別、地域別、セグメント予測、2025年～2033年
出版日: 2025年07月31日
発行: Grand View Research
ページ情報: 英文 118 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

関節内補充療法市場のサマリー

世界の関節内補充療法の市場規模は、2024年に53億米ドルと推計され、2025年から2033年にかけてCAGR 6.21%で成長し、2033年には93億9,000万米ドルに達すると予測されています。関節内補充療法は、関節痛を緩和し、膝の機能状態を高めることを目的としています。

変形性関節症の罹患率の増加は、関節内補充療法の需要を促進する上で重要な役割を果たしています。変形性関節症は、慢性の退行性関節疾患であり、永続的な障害の主な原因です。変形性関節症は一般的に30歳以降に発症し、診断から10年以内に身体障害を伴う状態にまで進行します。2025年3月、Scientific Reports誌に掲載された論文では、Global Burden of Disease Study 2021の変形性関節症のデータが分析されています。この研究では、1990年の2,090万症例から2021年には4,660万症例へと世界のOA罹患率が急増し、障害とともに生きる年数も顕著に増加していることが報告されました。また、健康格差が拡大しており、女性やSDIの高い国、アジアのような地域でより高い負担が見られることも強調されました。

関節障害の発生率の上昇は、関節内補充療法市場の主要な促進要因です。人口の高齢化と座りっぱなしの生活スタイルにより、退行性疾患がより一般的になりつつあります。このため、症状の緩和をもたらす非外科的治療アプローチに対する需要が高まっています。関節内補充療法は、関節の潤滑性と可動性を改善することでこれに対処します。ヘルスケアシステムは、外科的介入を遅らせることの費用対効果を認識しています。2024年11月、Osteoarthritis and Cartilage誌に掲載された論文では、2020年には変形性関節症が世界人口の7.6％に影響を及ぼし、有病率は過去30年間で132.2％増加していることが強調されています。さらに、55歳以前に発症する早期発症OA症例が、新規診断の半数以上、YLD全体の26.1％を占めていることも指摘されています。

低侵襲治療への嗜好が市場拡大に寄与しています。患者や医療提供者は、回復時間の短縮や合併症の少ない手技を選ぶようになってきています。関節内補充療法はこうしたニーズに合致しており、日常臨床での採用を後押ししています。製剤の開発が進んでいることも普及に影響しています。現在では、様々な患者プロファイルに対応できるよう、単回および複数回の注射レジメンが利用可能になっています。2024年4月、Cureus誌に掲載された研究では、2019年から2022年までのBRFSSデータを用いて米国成人の関節炎動向を分析しました。その結果、有病率の上昇と人口統計や健康状態による格差が浮き彫りになりました。これらの洞察は、痛み、合併症、回復時間の短縮を目的とした、関節炎に対する低侵襲手術（MIS）の採用拡大を裏付けています。

ヘルスケア提供者の間での意識の高まりと体系化された償還政策が、市場の成長をさらに後押ししています。継続的な臨床検証により、関節内補充療法は標準治療プロトコールに広く受け入れられるようになりました。これにより、関節変性の早期段階での使用が促進されています。市場各社は、高まる臨床需要に応えるため、製品ラインナップの拡充で対応しています。各地域の規制当局の支援により、主要市場での製品供給が促進されています。2024年1月、生化学工業株式会社は、新規架橋ヒアルロン酸技術を用いた多回注射による関節内補充療法製品の強化について、Anika Therapeutics社および他の2つのメーカーとの共同研究を発表しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 関節内補充療法市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 補助市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 関節内補充療法：市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTLE分析

第4章 関節内補充療法市場セグメント分析、製品別、2021～2033年

  • 定義と範囲
  • 製品別市場シェア分析、2024年および2033年
  • セグメントダッシュボード
  • 世界の関節内補充療法市場（製品別、2021～2033年）
  • 1回注射
    • 市場推計・予測（2021～2033年）
  • 3回の注射
    • 市場推計・予測（2021～2033年）
  • 5回の注射
    • 市場推計・予測（2021～2033年）

第5章 関節内補充療法市場セグメント分析、最終用途別、2021～2033年

  • 定義と範囲
  • セグメントダッシュボード
  • 世界の関節内補充療法市場（最終用途別、2021～2033年）
  • 病院
    • 市場推計・予測（2021～2033年）
  • 整形外科クリニック/ASC
    • 市場推計・予測（2021～2033年）

第6章 関節内補充療法市場セグメント分析、地域別、2021～2033年

  • 地域別市場シェア分析、2024年および2033年
  • 地域市場ダッシュボード
  • 地域市場のスナップショット
  • 関節内補充療法市場シェア（地域別）、2024年および2033年：
  • 北米
    • 北米の関節内補充療法市場、2021～2033年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 欧州の関節内補充療法市場、2021～2033年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業分類
  • 企業プロファイル
  • ヒートマップ分析、2024年
  • 企業プロファイル
    • DePuy Synthes
    • Fidia Farmaceutici SpA
    • Sanofi
    • Anika Therapeutics, Inc.
    • SEIKAGAKU CORPORATION
    • Zimmer Biomet
    • Smith &Nephew PLC
    • Ferring Pharmaceutical BV
    • Lifecore Biomedical, LLC（Landec）
    • LG Life Sciences Ltd.
    • F. Hoffmann-La Roche Ltd.
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 North America Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 4 North America Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 5 U.S. Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 6 U.S. Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 7 Canada Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 8 Canada Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 9 Mexico Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 10 Mexico Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 11 Europe Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 12 Europe Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 13 UK Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 14 UK Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 15 Germany Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 16 Germany Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 17 France Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 18 France Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 19 Italy Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 20 Italy Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 21 Spain Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 22 Spain Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 23 Sweden Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 24 Sweden Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 25 Denmark Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 26 Denmark Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 27 Norway Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 28 Norway Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 29 Asia Pacific Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 30 Asia Pacific Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 31 Japan Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 32 Japan Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 33 China Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 34 China Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 35 India Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 36 India Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 37 Australia Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 38 Australia Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 39 South Korea Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 40 South Korea Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 41 Thailand Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 42 Thailand Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 43 Latin America Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 44 Latin America Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 45 Brazil Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 46 Brazil Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 47 Argentina Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 48 Argentina Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 49 MEA Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 50 MEA Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 51 South Africa Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 52 South Africa Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 53 Saudi Arabia Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 54 Saudi Arabia Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 55 UAE Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 56 UAE Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)
  • Table 57 Kuwait Viscosupplementation market estimates and forecasts, by product, 2021 - 2033 (USD Million)
  • Table 58 Kuwait Viscosupplementation market estimates and forecasts, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Viscosupplementation market: outlook
  • Fig. 8 Viscosupplementation competitive insights
  • Fig. 9 Ancillary market outlook
  • Fig. 10 Viscosupplementation market driver impact
  • Fig. 11 Viscosupplementation market restraint impact
  • Fig. 12 Porter's Analysis
  • Fig. 13 PESTLE Analysis
  • Fig. 14 Viscosupplementation market: Product movement analysis
  • Fig. 15 Viscosupplementation market: Product outlook and key takeaways
  • Fig. 16 Single injection market estimates and forecast, 2021 - 2033
  • Fig. 17 Five injection market estimates and forecast, 2021 - 2033
  • Fig. 18 Toe intramedullary implants market estimates and forecast, 2021 - 2033
  • Fig. 19 Three injection market estimates and forecast, 2021 - 2033
  • Fig. 20 Scaphoid bone implants market estimates and forecast, 2021 - 2033
  • Fig. 21 Viscosupplementation market: End Use movement analysis
  • Fig. 22 Viscosupplementation market: End Use outlook and key takeaways
  • Fig. 23 Orthopedic Clinic/ASCs market estimates and forecasts, 2021 - 2033
  • Fig. 24 Hospitals market estimates and forecasts,2021 - 2033
  • Fig. 25 Global viscosupplementation market: Regional movement analysis
  • Fig. 26 Global viscosupplementation market: Regional outlook and key takeaways
  • Fig. 27 North America viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Key country dynamics
  • Fig. 29 U.S. viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Key country dynamics
  • Fig. 31 Canada viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Key country dynamics
  • Fig. 33 Mexico viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Europe viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Key country dynamics
  • Fig. 36 UK viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Key country dynamics
  • Fig. 38 Germany viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 Spain viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 France viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 Italy viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Norway viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 Denmark viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Sweden viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Asia Pacific viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Japan viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 China viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 India viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Australia viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 South Korea viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Thailand viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Latin America viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Brazil viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Argentina viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 MEA viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 South Africa viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Saudi Arabia viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 UAE viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Kuwait viscosupplementation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Key company categorization
  • Fig. 79 Heat map analysis, 2024
目次
Product Code: GVR-1-68038-982-1

Viscosupplementation Market Summary

The global viscosupplementation market size was estimated at USD 5.30 billion in 2024 and is projected to reach USD 9.39 billion by 2033, growing at a CAGR of 6.21% from 2025 to 2033. Viscosupplementation aims to alleviate joint pain and enhance the functional state of the knee.

The growing incidence of osteoarthritis plays a significant role in driving the demand for viscosupplementation. Osteoarthritis, a chronic degenerative joint disease, is the primary cause of enduring disability. It typically emerges after the age of 30 and can progress to a disabling condition within a decade of diagnosis. In March 2025, an article published in Scientific Reports analyzed osteoarthritis data from the Global Burden of Disease Study 2021. The study reported a sharp rise in global OA incidence from 20.9 million cases in 1990 to 46.6 million in 2021, with a notable increase in years lived with disability. It also highlighted growing health inequalities, with a higher burden seen among women, in high SDI countries, and regions like Asia.

The rising incidence of joint disorders is a key driver of the viscosupplementation market. Degenerative conditions are becoming more common due to aging populations and sedentary lifestyles. This is leading to greater demand for non-surgical treatment approaches that provide symptom relief. Viscosupplementation addresses this by improving joint lubrication and mobility. Healthcare systems are recognizing the cost-effectiveness of delaying surgical intervention. In November 2024, an article in Osteoarthritis and Cartilage highlighted that osteoarthritis affected 7.6% of the global population in 2020, with prevalence increasing by 132.2% over the past 30 years. Moreover, it is noted that early-onset OA cases, occurring before age 55, accounted for over half of new diagnoses and 26.1% of total YLDs.

Preference for minimally invasive treatment options is contributing to market expansion. Patients and providers are increasingly opting for procedures that offer reduced recovery time and fewer complications. Viscosupplementation aligns with these needs, supporting its adoption in routine clinical practice. Ongoing developments in formulation are also influencing uptake. Single and multiple-injection regimens are now available to accommodate different patient profiles. In April 2024, a study published in Cureus analyzed arthritis trends among U.S. adults using BRFSS data from 2019 to 2022. The findings underscored rising prevalence and disparities by demographics and health status. These insights support growing adoption of minimally invasive surgeries (MIS) for arthritis, aimed at reducing pain, complications, and recovery time.

Growing awareness among healthcare providers and structured reimbursement policies are further supporting market growth. Continued clinical validation has led to broader acceptance of viscosupplementation in standard care protocols. This is encouraging its use at earlier stages of joint degeneration. Market players are responding with expanded product offerings to meet rising clinical demand. Regional regulatory support has facilitated product availability across key markets. In January 2024, Seikagaku Corporation announced collaborations with Anika Therapeutics and two other manufacturers to enhance multi-injection viscosupplementation products using novel cross-linked hyaluronic acid technologies.

Global Viscosupplementation Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global viscosupplementation market report based on product, end use, and region:

  • Product Outlook (Revenue in USD Billion, 2021 - 2033)
  • Single Injection
  • Three Injection
  • Five Injection
  • End Use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospitals
  • Orthopedic Clinics/ASCs
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment scope
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.7. Research Assumptions
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. End Use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Viscosupplementation Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of osteoarthritis among aging populations
      • 3.2.1.2. Rising demand for non-surgical pain management options in orthopedics
      • 3.2.1.3. Advancements in hyaluronic acid formulations improving product efficacy
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatment limiting access in low- and middle-income countries
      • 3.2.2.2. Limited long-term effectiveness leading to physician skepticism and guideline restrictions
  • 3.3. Viscosupplementation: Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTLE Analysis

Chapter 4. Viscosupplementation Market Segment Analysis, By Product, 2021 - 2033 (USD Million)

  • 4.1. Definition and Scope
  • 4.2. Product Market Share Analysis, 2024 & 2033
  • 4.3. Segment Dashboard
  • 4.4. Global viscosupplementation market, by product, 2021 to 2033
  • 4.5. Single injection
    • 4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.6. Three injection
    • 4.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.7. Five injection
    • 4.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Viscosupplementation Market Segment Analysis, By End Use, 2021 - 2033 (USD Million)

  • 5.1. Definition and Scope
  • 5.2. Segment Dashboard
  • 5.3. Global viscosupplementation market, by End Use, 2021 to 2033
  • 5.4. Hospitals
    • 5.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.5. Orthopedic Clinic/ASCs
    • 5.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Viscosupplementation Market Segment Analysis, By Region, 2021 - 2033 (USD Million)

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Regional Market Snapshot
  • 6.4. Viscosupplementation Market Share by Region, 2024 & 2033:
  • 6.5. North America
    • 6.5.1. North America viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.5.2. U.S.
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Scenario
      • 6.5.2.4. U.S. viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. Canada viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Mexico viscosupplementation market, 2021 - 2033 (USD Million)
  • 6.6. Europe
    • 6.6.1. Europe viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.6.2. UK
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Scenario
      • 6.6.2.4. UK viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.6.3. Germany
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. Germany viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.6.4. France
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. France viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.6.5. Italy
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Italy viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.6.6. Spain
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Spain viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.6.7. Norway
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Scenario
      • 6.6.7.4. Norway viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.6.8. Sweden
      • 6.6.8.1. Key Country Dynamics
      • 6.6.8.2. Regulatory Framework
      • 6.6.8.3. Competitive Scenario
      • 6.6.8.4. Sweden viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.6.9. Denmark
      • 6.6.9.1. Key Country Dynamics
      • 6.6.9.2. Regulatory Framework
      • 6.6.9.3. Competitive Scenario
      • 6.6.9.4. Denmark viscosupplementation market, 2021 - 2033 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key Country Dynamics
      • 6.7.1.2. Regulatory Framework
      • 6.7.1.3. Competitive Scenario
      • 6.7.1.4. Japan viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Scenario
      • 6.7.2.4. China viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Scenario
      • 6.7.3.4. India viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key Country Dynamics
      • 6.7.4.2. Regulatory Framework
      • 6.7.4.3. Competitive Scenario
      • 6.7.4.4. Australia viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key Country Dynamics
      • 6.7.5.2. Regulatory Framework
      • 6.7.5.3. Competitive Scenario
      • 6.7.5.4. South Korea viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key Country Dynamics
      • 6.7.6.2. Regulatory Framework
      • 6.7.6.3. Competitive Scenario
      • 6.7.6.4. Thailand viscosupplementation market, 2021 - 2033 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key Country Dynamics
      • 6.8.1.2. Regulatory Framework
      • 6.8.1.3. Competitive Scenario
      • 6.8.1.4. Brazil viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Scenario
      • 6.8.2.4. Argentina viscosupplementation market, 2021 - 2033 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key Country Dynamics
      • 6.9.1.2. Regulatory Framework
      • 6.9.1.3. Competitive Scenario
      • 6.9.1.4. South Africa viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key Country Dynamics
      • 6.9.2.2. Regulatory Framework
      • 6.9.2.3. Competitive Scenario
      • 6.9.2.4. Saudi Arabia viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key Country Dynamics
      • 6.9.3.2. Regulatory Framework
      • 6.9.3.3. Competitive Scenario
      • 6.9.3.4. UAE viscosupplementation market, 2021 - 2033 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key Country Dynamics
      • 6.9.4.2. Regulatory Framework
      • 6.9.4.3. Competitive Scenario
      • 6.9.4.4. Kuwait viscosupplementation market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Profiles
  • 7.4. Heatmap Analysis, 2024
  • 7.5. Company Profile
    • 7.5.1. DePuy Synthes
      • 7.5.1.1. Company Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic initiatives
    • 7.5.2. Fidia Farmaceutici S.p.A
      • 7.5.2.1. Company Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic initiatives
    • 7.5.3. Sanofi
      • 7.5.3.1. Company Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic initiatives
    • 7.5.4. Anika Therapeutics, Inc.
      • 7.5.4.1. Company Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic initiatives
    • 7.5.5. SEIKAGAKU CORPORATION
      • 7.5.5.1. Company Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic initiatives
    • 7.5.6. Zimmer Biomet
      • 7.5.6.1. Company Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic initiatives
    • 7.5.7. Smith & Nephew PLC
      • 7.5.7.1. Company Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic initiatives
    • 7.5.8. Ferring Pharmaceutical B.V.
      • 7.5.8.1. Company Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic initiatives
    • 7.5.9. Lifecore Biomedical, LLC (Landec)
      • 7.5.9.1. Company Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic initiatives
    • 7.5.10. LG Life Sciences Ltd.
      • 7.5.10.1. Company Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic initiatives
    • 7.5.11. F. Hoffmann-La Roche Ltd.
      • 7.5.11.1. Company Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Product Benchmarking
      • 7.5.11.4. Strategic initiatives